| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Carboplatin is a platinum-based chemotherapy drug, structurally related to cisplatin. Advantages Over Cisplatin: • Compared to cisplatin, carboplatin is associated with a more favorable side-effect profile, particularly with regard to reduced nephrotoxicity (renal toxicity). • However, it may still cause bone marrow suppression, so careful monitoring of blood counts is essential. Carboplatin is a key platinum-based chemotherapy agent that interferes with cancer cell DNA, leading to cell death. Its relatively favorable toxicity profile, compared to cisplatin, makes it a popular choice for treating a variety of solid tumors such as ovarian, lung, head and neck, bladder, and certain cases of testicular cancers. Due to its side-effect profile, particularly bone marrow suppression, patients receiving carboplatin require careful monitoring and dosage adjustments based on their renal function and other clinical factors. Carboplatin — Carboplatin is a second-generation platinum coordination complex used as a cytotoxic antineoplastic. It functions primarily as a DNA-crosslinking platinum drug after intracellular activation by aquation, generating reactive platinum species that form covalent DNA adducts. It is formally classified as a platinum-based chemotherapy agent, often grouped with alkylating-like agents despite having distinct coordination chemistry. Standard abbreviations include CBDCA and the trade name Paraplatin. Clinically it is administered intravenously, usually by body-surface-area or Calvert AUC-based dosing, and is widely used in ovarian cancer and many platinum-containing combination regimens for lung and other solid tumors. Relative to cisplatin, carboplatin is generally less nephrotoxic, neurotoxic, and emetogenic, but its dominant dose-limiting toxicity is myelosuppression, especially thrombocytopenia and neutropenia. Primary mechanisms (ranked):
Bioavailability / PK relevance: Carboplatin is not meaningfully orally bioavailable and is used intravenously. It is more chemically stable and aquates more slowly than cisplatin, which contributes to different toxicity kinetics. Clearance is strongly linked to renal function, making exposure-guided dosing clinically important; Calvert AUC-based dosing is standard in many settings. Systemic exposure is readily achievable because this is an approved infused cytotoxic, but therapeutic use is constrained by marrow toxicity rather than by poor delivery. In-vitro vs systemic exposure relevance: Mechanism is concentration- and exposure-time-dependent, but unlike many phytochemicals, clinically relevant systemic exposure is achievable with standard infusion dosing. Even so, some in-vitro studies use prolonged or supra-clinical concentrations that may exaggerate secondary signaling effects relative to the core DNA-adduct mechanism seen in patients. Clinical evidence status: Established standard-of-care cytotoxic chemotherapy with extensive human evidence and regulatory approval. Strongest formal label support is for ovarian carcinoma, while broader real-world and guideline-supported use includes multiple solid tumors in combination regimens. It is frequently used as backbone chemotherapy or as a substitute for cisplatin when toxicity profile or renal tolerance is limiting. Mechanistic table
P: 0–30 min |
| Source: |
| Type: |
| Cellular stress response related to the endoplasmic reticulum (ER) stress, which involves protein folding, quality control, and signaling pathways. The unfolded protein response (UPR) is the cells' way of maintaining the balance of protein folding in the endoplasmic reticulum. (UPR) is triggered by the presence of misfolded proteins in the endoplasmic reticulum. The UPR is a cellular stress response activated by the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER). - It is primarily mediated by three ER-resident sensors: IRE1α, PERK, and ATF6. Cancer cells often experience high levels of protein synthesis, hypoxia, nutrient deprivation, and oxidative stress, all of which can activate the UPR. – Numerous studies have reported that key UPR components (e.g., GRP78/BiP, IRE1α, PERK, CHOP) are overexpressed in various malignancies such as breast, pancreatic, lung, and prostate cancers. Unfolded Protein Response is typically upregulated in cancers and is associated with poorer prognosis due to its role in promoting cell survival, adaptation to stress, and therapeutic resistance. Although the UPR harbors the potential for tumor-suppressive (apoptotic) effects under severe stress conditions, its predominant activation in tumors supports an adaptive, protumorigenic state that facilitates cancer progression. Targeting UPR components and modulating this balance remain promising therapeutic strategies. |
| 5862- | carbop, | Cisplatin, | Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:265 Target#:459 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid